HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.